Dihydroergotamine mesylate intranasal - Novartis

Drug Profile

Dihydroergotamine mesylate intranasal - Novartis

Alternative Names: Dihydroergotamine mesylate nasal spray - Novartis; Dihydroergotamine-mesylate; Migranal

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 02 Jul 2013 Launched prior to this date for Migraine in Austria (Intranasal)
  • 02 Jul 2013 Launched prior to this date for Migraine in Canada (Intranasal)
  • 27 Jun 2013 Zogenix & Valeant Pharmaceuticals agree to co-promote dihydroergotamine mesylate nasal spray in USA for Migraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top